Imputation of missing data from unstructured notes
Date of Initial Dx
Imputation of index event
Line of Therapy
Regimen or progression-based drug classes
Identify root cause of product switching
Predict factors driving patients’ brand decision
Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.
melanoma research study
Burden of Illness of Adjuvant Therapy for Advanced Melanoma
Stage I-III melanoma at high risk of progression is treated with the approved systemic adjuvant therapy. This study described treatment patterns, clinical outcomes, and healthcare costs among these patients.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.